ABOUT ENDECE

We are experts at discovery and early clinical development.

We are experts at discovery and early clinical development. ENDECE is led by an experienced management team with a proven ability to develop novel therapeutics. We characterize small-molecule compounds from the ENDECE proprietary library and associate their biological activity with therapeutic targets they may impact:

OUR PROCESS
  • Identify compounds that impact specific gene sets within therapeutic targets
  • Complete pre-clinical and initiate Phase 1 clinical studies
  • Secure a licensing partner to complete clinical development and commercialization
About Endece

ENDECE SCIENTISTS IDENTIFIED NDC-1308, A NOVEL COMPOUND FROM THE ENDECE LIBRARY, WITH THE POTENTIAL TO REGULATE GENES THAT PROMOTE REMYELINATION. THIS MULTIPLE TARGET APPROACH, VALIDATED IN A PRECLINICAL MODEL OF MULTIPLE SCLEROSIS (MS), COULD BE THE FIRST DRUG CAPABLE OF INDUCING REMYELINATION OF DEMYELINATED NERVES IN PATIENTS WITH MS.

Management Team

MANAGEMENT TEAM

Our management team consists of executive leaders with deep experience and a proven ability to develop innovative therapies and technologies.
Scientific Advisory Board

SCIENTIFIC ADVISORY BOARD

We work with world-class experts who share our passion for developing clinical advances in areas of unmet need, such as multiple sclerosis.
Networks

NETWORKS

The ENDECE collaborative business model taps into a proven network of resources covering all areas of the newest technologies whenever they are needed.
Corporate Compliance

CORPORATE COMPLIANCE

We are committed to the highest scientific and ethical standards.